Observational Trial Tolerability and Efficacy of Resiquimod Gel in Patients Treated for Actinic Keratosis.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lars E French, MD
University Clinic of Dermatology, Zurich
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hauttumorcentrum Charité (htcc)
Berlin, Germany
- Medizinisches Zentrum Bonn - Friedensplatz
Bonn, Germany
- Hautzentrum
Düsseldorf, Germany
- Johannes Wesling Klinikum Minden
Minden, Germany
- Klinikum Vest Gmbh Knappschaftskrankenhaus
Recklinghausen, Germany
- Universitätsspital Basel
Basel, Switzerland
- Inselspital
Bern, Switzerland
- Kantonsspital St.Gallen
Sankt Gallen, Switzerland
- Universitaetsspital Zurich
Zurich, Switzerland
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2013
- Primary completion
- 30 Jun 2013
- Completion
- 30 Sept 2013
- Last update posted
- 3 Aug 2016
- Registered enrollment
- 16
- Registry id
- NCT01806961
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.